Rimegepant For Endometriosis Pain

Part of paid clinical trials in Phoenix, Arizona.

Sponsor: Mayo Clinic
Study ID: NCT07795125
Phase: PHASE2
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Endometriosis
Endometriosis-related Pain

Eligibility Criteria

Sex: FEMALE
Age: 18 Years - 45 Years
Healthy Volunteers: Not accepted

Interventions

Rimegepant 75 MG — DRUG
Rimegepant 75 mg oral capsule administered every other day for 12 weeks
Placebo — DRUG
Matching placebo oral capsule administered every other day for 12 weeks.

Study Details

The purpose of this study is to evaluate the efficacy of rimegepant 75 mg versus placebo in reducing endometriosis-associated pain (EAP) in women with moderate-to-severe pain and histologically confirmed endometriosis.

Key Dates

First listed: Aug 31, 2026
Start date: Sep 30, 2026
Status verified: Aug 2026
Primary completion: Mar 30, 2031
Completion: Sep 30, 2031

Study Design

Enrollment: 132 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Rimegepant
Participants randomized to this arm will receive Rimegepant 75 mg administered orally every other day for 12 weeks.
Placebo Comparator: Placebo
Participants randomized to this arm will receive matching placebo capsules administered orally every other day for 12 weeks.